Scarica l'app Stockscreener
65.51
1.71%
1.10
Dopo l'orario di chiusura:
65.00
-0.51
-0.78%
Precedente Chiudi:
$64.41
Aprire:
$64.41
Volume 24 ore:
2.20M
Relative Volume:
1.12
Capitalizzazione di mercato:
$12.68B
Reddito:
$3.29B
Utile/perdita netta:
$268.74M
Rapporto P/E:
47.80
EPS:
1.3704
Flusso di cassa netto:
$759.12M
1 W Prestazione:
-1.38%
1M Prestazione:
-4.89%
6M Prestazione:
+7.59%
1 anno Prestazione:
+20.20%
Intervallo 1D:
$63.57
$65.59
Intervallo di 1 settimana:
$63.57
$66.64
Portata 52W:
$49.26
$70.98
Biomarin Pharmaceutical Inc Stock (BMRN) Company Profile
Nome
Biomarin Pharmaceutical Inc
Settore
Industria
Telefono
(415) 506-6700
Indirizzo
105 DIGITAL DRIVE, NOVATO, CA
Compare BMRN vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BMRN
Biomarin Pharmaceutical Inc
|
65.51 | 12.47B | 3.29B | 268.74M | 759.12M | 1.3704 |
VRTX
Vertex Pharmaceuticals Inc
|
514.56 | 132.08B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
793.26 | 83.15B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
984.04 | 62.71B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
136.62 | 54.14B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
203.35 | 44.51B | 742.00K | -1.37B | -1.07B | -7.0731 |
Biomarin Pharmaceutical Inc Stock (BMRN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-27 | Ripresa | Morgan Stanley | Overweight |
| 2026-01-28 | Ripresa | Barclays | Overweight |
| 2026-01-20 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2025-12-03 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2025-11-06 | Downgrade | Stifel | Buy → Hold |
| 2025-09-08 | Iniziato | H.C. Wainwright | Neutral |
| 2025-09-03 | Iniziato | Raymond James | Outperform |
| 2025-07-03 | Ripresa | Morgan Stanley | Overweight |
| 2025-02-24 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-10-30 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-08-20 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2024-05-17 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-05-14 | Iniziato | Evercore ISI | Outperform |
| 2023-11-15 | Iniziato | Wells Fargo | Overweight |
| 2023-10-23 | Aggiornamento | Bernstein | Underperform → Mkt Perform |
| 2023-09-28 | Iniziato | Raymond James | Mkt Perform |
| 2023-09-18 | Iniziato | UBS | Buy |
| 2023-07-27 | Iniziato | Scotiabank | Sector Perform |
| 2023-07-05 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2023-06-14 | Ripresa | Credit Suisse | Outperform |
| 2023-03-21 | Iniziato | Bernstein | Underperform |
| 2023-02-22 | Downgrade | Oppenheimer | Outperform → Perform |
| 2023-02-21 | Iniziato | Citigroup | Neutral |
| 2023-01-30 | Iniziato | BMO Capital Markets | Market Perform |
| 2023-01-18 | Iniziato | Canaccord Genuity | Hold |
| 2022-10-31 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2022-07-13 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-06-13 | Ripresa | Wedbush | Neutral |
| 2022-04-25 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2021-11-22 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2021-10-07 | Ripresa | Jefferies | Buy |
| 2021-09-09 | Aggiornamento | Stifel | Hold → Buy |
| 2021-06-04 | Ripresa | Robert W. Baird | Outperform |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2021-03-04 | Ripresa | Guggenheim | Buy |
| 2021-03-01 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2020-08-20 | Downgrade | Citigroup | Buy → Neutral |
| 2020-08-20 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2020-08-19 | Downgrade | Evercore ISI | Outperform → In-line |
| 2020-08-19 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-08-19 | Downgrade | Stifel | Buy → Hold |
| 2020-07-08 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-07-06 | Reiterato | Citigroup | Buy |
| 2020-01-28 | Iniziato | BMO Capital Markets | Market Perform |
| 2020-01-27 | Iniziato | BMO Capital Markets | Market Perform |
| 2020-01-24 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2019-11-27 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2019-11-12 | Iniziato | SunTrust | Buy |
| 2019-10-17 | Ripresa | BofA/Merrill | Buy |
| 2019-05-23 | Ripresa | Citigroup | Buy |
| 2019-04-09 | Ripresa | Raymond James | Outperform |
| 2019-01-02 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2018-12-14 | Iniziato | Wolfe Research | Outperform |
| 2018-10-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-08-07 | Reiterato | Stifel | Buy |
| 2018-08-03 | Reiterato | Stifel | Buy |
Mostra tutto
Biomarin Pharmaceutical Inc Borsa (BMRN) Ultime notizie
BMRN: Blockbuster growth, pipeline innovation, and AI-driven efficiencies drive future outlook - TradingView
BioMarin at Citi summit: voxzogo drives growth as pipeline widens By Investing.com - Investing.com India
BMRN: Portfolio expansion, robust growth, and pipeline innovation drive long-term outlook - TradingView
BioMarin at Cantor conference: growth plan widens beyond Voxzogo By Investing.com - Investing.com India
Ascendis Pharma Says Growth Drug Shows Benefits in Infants - Benzinga
H.C. Wainwright reiterates Biomarin stock rating at neutral - Investing.com
H.C. Wainwright reiterates Biomarin stock rating at neutral By Investing.com - Investing.com India
BioMarin at Wells Fargo conference: growth, pipeline and integration By Investing.com - Investing.com India
BMRN: Strong growth, pipeline expansion, and global market execution drive future momentum - TradingView
(BMRN) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
BioMarin Pharmaceutical Inc. Announces Positive Results Of Phase 3 VOXZOGO Study In Hypochondroplasia - marketscreener.com
BioMarin Announces Positive Results of Phase 3 VOXZOGO® Study in Hypochondroplasia Published in NEJM Evidence - Investing News Network
Ten healthcare stocks with A-rated valuations and strong revenue growth - TradingView
A drug helped children with a rare growth disorder grow 2.33 cm more per year - Stock Titan
Don't Ignore The Insider Selling In BioMarin Pharmaceutical - simplywall.st
RARE Stock Crashes In Worst Day Ever — ‘Pharma Bro’ Martin Shkreli Calls It ‘Very Cheap,’ Floats BioMarin Buyout - Stocktwits
Achondroplasia Market Analysis Report 2026: Emerging Pipeline Intensifies Competition, Featuring Ascendis Pharma, BioMarin Pharmaceutical, QED Therapeutics (BridgeBio), Novartis, Kyowa Kirin, RIBOMIC - Yahoo Finance
3 Reasons to Avoid BMRN and 1 Stock to Buy Instead - Yahoo Finance
Royalty Deal Could Be A Big Development For BioMarin Stock (BMRN) - simplywall.st
Weekly Recap: TransCon CNP license and Alesta Therapeutics acquisition - TradingView
BioMarin Pharmaceutical Inc. (BMRN) Stock Analysis: 37% Upside Potential Amid Robust Revenue Growth - DirectorsTalk Interviews
BioMarin Pharmaceutical (BMRN), What Is Behind The Fresh Attention? - simplywall.st
BioMarin (BMRN) Secured 20% U.S. Royalties on Yuviwel. Is Monetizing a Rival Better than Blocking It? - Yahoo Finance
EVP At BioMarin Pharmaceutical Sells $1.16M Of Stock - Benzinga
Ascendis Pharma (ASND) Settles Patent Fight And Wins Canadian Yorvipath Reimbursement Backing - Yahoo Finance
BioMarin (NASDAQ: BMRN) legal chief unloads 17,557 shares - Stock Titan
How BioMarin Turned a Competitive Threat Into a Royalty-Bearing Asset - Eastern Progress
Pharma Bro Martin Shkreli Says Ultragenyx Should Be M&A TargetUltragenyx Pharmaceutical (NASDAQ:RARE) - Benzinga
Officer at BioMarin (NASDAQ: BMRN) plans sale of 17,557 shares - Stock Titan
BioMarin to Participate in Upcoming Investor Conferences - Yahoo Finance
Analysts Conflicted on These Healthcare Names: Axsome Therapeutics (AXSM), BioMarin Pharmaceutical (BMRN) and Envista Holdings (NVST) - The Globe and Mail
CASI Pharmaceuticals (CASIF) sells Alesta stake to BioMarin, with possible future milestone payouts - Stock Titan
How BioMarin’s Navepegritide Settlement and Royalty Deal with Ascendis Could Shape BioMarin (BMRN) Investors - simplywall.st
Piper Sandler raises BioMarin stock price target on IP settlement By Investing.com - Investing.com South Africa
BioMarin To Get Royalties From Ascendis Under IP Settlement - Law360
Oppenheimer raises Ascendis Pharma stock price target on settlement - Investing.com
BioMarin announces global settlement with Ascendis - The Pharma Letter
BioMarin Completes Alesta Therapeutics Acquisition, Adding HPP Drug Candidate ALE1 - citybiz
BioMarin Announces Close of the Alesta Therapeutics Acquisition - Investing News Network
4 Rare Disease Drugmakers With Strong Long-Term Growth Prospects - Eastern Progress
Piper Sandler raises BioMarin stock price target on IP settlement - Investing.com
BioMarin completes acquisition of Alesta, making it a wholly owned subsidiary - TradingView
Canaccord reiterates BioMarin stock rating on Ascendis settlement By Investing.com - Investing.com Australia
Canaccord reiterates BioMarin stock rating on Ascendis settlement - Investing.com
BioMarin Secures Double-Digit Yuviwel Royalties In Settlement With Ascendis - insights.citeline.com
Ascendis Pharma (NASDAQ: ASND) strikes global YUVIWEL settlement with BioMarin - stocktitan.net
Ascendis Pharma A/S and Biomarin Pharmaceutical Inc. Enter Binding Term Sheet for Global Settlement and License Agreement Related to Yuviwel and Navepegritide-Related Products - marketscreener.com
Morgan Stanley reiterates BioMarin stock rating on settlement value By Investing.com - Investing.com Nigeria
Ascendis pays 20% royalties in patent settlement with BioMarin - fiercepharma.com
BioMarin Pharma gains with analyst upgrade, pat... - Pluang
Jefferies raises BioMarin stock price target on Ascendis settlement - Investing.com
Biomarin Pharmaceutical Inc Azioni (BMRN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):